Overview

China Pharma IP Summit is a serial event dedicated to pharmaceutical IP protection, and so far we have hold 2 sessions in the year of 2016 and 2017. Government agencies, pharmaceutical/biotech companies, law firms/ IP agencies and other IP solution providers have been invited to attend and we discussed lots of hot issues. Meanwhile, the event has been a good networking platform for industry experts both from local China and abroad.

2017 is a year of great significance in China pharmaceutical industry. On May 2017, China Food and Drug Administration (CFDA) issued Policy Notice No. 55, entitled “Policies Relevant to the Protection of the Rights and Interests of Innovators for the Encouragement of Innovation in Drugs and Medical Devices”. On October 2017, the Opinions on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation was officially issued, clearly putting forward the establishing patent linkage system, launching pilot program on drug patent extension, completing data protection and implementing list of marketed drugs. At the moment, China is conducting legislation for patent linkage and patent extension, which draws lots of attention.

In terms of intellectual property judicial, on Feb 2018, General Office of the CPC and General Office of the State Council issued Strengthening the Intellectual Property Judicial Reform and Innovation, which is the first guiding document regarding to intellectual property judicial. Pharmaceutical is heavily relied on IP protection, and we predict the guiding document will have influence on pharmaceutical IP litigation in China.

Based on the background, we are glad to inform that 3rd China Pharma IP Summit 2018 will be hold on 24th -26th October in Beijing, providing a platform to discuss updated policies and hot issues.

Through the event, you will have chance to:

1. Follow the latest development of patent linkage and patent term extension reform in China

2. Understand the differences and updated requirements of examination standards, patent invalidation, patent litigation in China, US, EU, Japan and other region.

3. Learn IP management experience from pharmaceutical company

4. Meet you clients/partners fact to face and interact with industry peers

The participants are mainly from pharma/biotech companies, law firms, IP/patent agencies, IP/patent solution providers, governments, relevant associations, research institutes. If you would like to attend or sponsor our summit, please feel free to call / email us to reserve your seats ASAP!

Thanks again for your attention and looking forward to your participation!



Agenda:

Day1:24, Oct. 2018
Day1 Morning: Policies Updated in China


0730 Registration


0830 Chairman Opening Remarks


0840


Interpretation of the Opinions on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation and the Latest Supportive Documents

China Food and Drug Administration (inviting)



0925

The Latest Development of Patent Term Extension Reform in China

CFDA is conducting legislation for patent term extension reform, and the pilot program is expected to be launched within this year. We will invite expert to share the latest development, including the product and patent scope for patent extension, the condition for extension, the extension period calculation and the opposition proceedings and so on.

Speaker is inviting



1010
Coffee Break


1045

Updated Implementation Rules for Patent Linkage System in China

You can tell China government is devoted to pushing the establishment of patent linkage: on May 2017, CFDA issued “Policies Relevant to the Protection of the Rights and Interests of Innovators for the Encouragement of Innovation in Drugs and Medical Devices”. On October 2017, the Opinions on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation was officially issued. On December 2017, the first edition of List of Marketed Medicine was released. Hopefully, more detailed implementation rules are expected to be released as CFDA is also conducting legislation for patent linkage.

Speaker is inviting



1130

Topic Is Confirming

CCPIT PATENT AND TRADEMARK LAW OFFICE

1205

The Patent Linkage for Pharmaceuticals -A Worldwide Perspective

Yehudah Livneh, Strategic IP Consultant;

Former General Patent Counsel and VP Corporate IP and Legislative Affairs, Teva Pharmaceuticals



1240 Lunch Buffet


Day 1 Afternoon: Focus on US


1400

Recent US Legal Developments and How These Developments Are Affecting The Pharmaceutical Companies

Philip Johnson, Found and Principal of Johnson-IP Strategy and Consulting;
Former SVP- IP Policy & Strategy of Johnson & Johnson – Law Department (retired in 2017)



1435

Topic is Confirming

Shashank Upadhye, Founding Partner, Amin Talati Upadhye, LLP



1510


The ANAD Litigation Comparison Between China Generic and India Generic in US

LexisNexis



1545

Coffee Break



1620

Development and Implication of Para IV Litigation Cases in US

Christopher Griffith, Founding Partner, Green, Griffith & Borg-Breen LLP



1655

Topic is Confirming

Alyson Wooten, Counsel, Kilpatrick Townsend & Stockton LLP

1730



Q&A Session: Practical Tips for Litigation in US

In the afternoon, we introduce the examination, litigation in US, but we think participants still have questions need to be answered. We will invite in-house IP counsel, law firms to the stage (give priority to speakers) for this part Q&A.

1800 End of Day 1


1830 Cocktail  (Sponsored  by Womble Bond Dickinson (US) LLP


Day2: 25, Oct. 2018
Day2 Morning: Focus on China


0830


Chairman Opening Remark

Chairman: Li Wu, Senior Consultant, AnJie Law Firm



0840

Pharmaceutical High Value Patent Cultivation

Qiujuan Ma, Director for Pharmaceutical, Patent Examination Cooperation Center of SIPO



0920

Pharmaceutical Patent Trial in China

Chi Su, Director of IP Case Guidance Research (Beijing) Base of the Supreme Peoples Court and President of Beijing IP Law Association; First President, Beijing Intellectual Property Court (Retired in Dec. 2017)



1000

Coffee Break



1035


Topic is Confirming

HENG DU LAW FIRM



1110

Challenge and Strategy for China Pharmaceutical IP Department

To prepare the new policies such as patent linkage, regulatory data protection and patent extension, the IP department should take new moves to meet the opportunities. We will invite in-house IP counsel from China to share the suggestion.

aoxi Lin, IP Director, HEC Group



1145

Panel Discussion: Hot Cases of Pharmaceutical Patent Invalidation in China and Implication

Moderator: Li Wu, Senior Consultant, AnJie Law Firm

Panelists are inviting



1235 Lunch


Day2 Afternoon: Focus on EU


1400

The Latest Developments at EPO (including pertinent case law)

Klaus-Peter Döpfer, Director Biotechnology, Sector Healthcare-Biotechnology-Chemistry, EPO



1435

The Supplementary Protection Certificate in EU and Potential Modification

The European Commission has collected the public consultation on January 2018, for potential modification of the SPC and patent exemption framework in the EU. SPC is a unique patent protection in EU, and play an important role in innovative pharmaceutical and plant protection products. We will follow this closely.

Andreas Oser, Managing Partner, Prüfer & Partner

1510




Updated Development of Unitary Patent and Unified Patent Court in EU

The 1st edition of "Unitary Patent Guide" was issued in August 2017, providing an outline of the procedure involved in obtaining a Unitary Patent. The Guide also deals with the accessory procedures such as compensation scheme for translation costs, statement on licenses of right, and renewal fees and so on. We will invite EU law firm to introduce the unitary patent, as well as the latest development of UPC.

Jonathan Atkinson, Partner, HGF Limited



1545

Coffee Break



1620

Topic To Be Confirmed



1655 Q&A Session: Practical Tips for Litigation in EU?

It is same as day1 afternoon, we save this part for participants Q&A for their questions in EU. 4-5 guests will be invited to the stage to answer the question (give priority to speakers)



1800 End of Day Two




Day3: 26, Oct. 2018
Day3 Morning: Other Region


0830

Chairman Opening Remark



0840

Pharmaceutical Patent Protection and Patent Term Extension Regime in Japan


Koichiro Morihira, Head of Intellectual Property, Astellas Pharma Inc.

Chair of Intellectual Property Committee, Japan Pharmaceutical Manufacturers Association




0920

Optimizing Overseas Pharma M&A DecisionsBig Data Supported IP Due Diligence


Chieh-Mei Wang, Vice President, ScienbiziP Consulting (Shen Zhen) Co., Ltd.




1000

Coffee Break



1035

The Generic Pharmaceutical in India and Patent Compulsory Licensing System

Mahendra B. Thakre, General Manager – IPR Legal, Mylan Laboratories Limited




1110

Topic is confirming



1145

Conference Closing Remark






 

  Media Partner